Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 5/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664143 | 0.96 | POLB (0.46) | L3MBTL1POLBGAAMAPTTDP1 | |
| SCHEMBL13664373 | 0.96 | POLB (0.46) | L3MBTL1POLBGAAMAPTTDP1 | |
| SCHEMBL13664403 | 0.94 | L3MBTL1 (0.46) | L3MBTL1POLBGAAMAPTTDP1 | |
| SCHEMBL13664329 | 0.92 | CNR1 (0.46) | L3MBTL1POLBGAAMAPTTDP1 | |
| SCHEMBL13664359 | 0.92 | POLB (0.44) | L3MBTL1POLBGAAMAPTTDP1 | |
| SCHEMBL13664400 | 0.92 | POLB (0.44) | L3MBTL1POLBGAAMAPTTDP1 | |
| SCHEMBL13664352 | 0.92 | GAA (0.44) | L3MBTL1POLBGAAMAPTTDP1 | |
| SCHEMBL13664435 | 0.92 | RHOC (0.43) | L3MBTL1POLBGAAMAPTTDP1 | |
| SCHEMBL13664351 | 0.92 | POLB (0.45) | L3MBTL1POLBGAAMAPTTDP1 | |
| SCHEMBL13664459 | 0.92 | MAPT (0.43) | L3MBTL1POLBGAAMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | GIPR, GPR119, GLP1R | L3MBTL1 3707/4885POLB 4851/4885GAA 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.